Abstract
The present invention discloses novel hydrogel-based technologies and methods for subcutaneous immunotherapy of allergic and autoimmune diseases which allows tolerogenic modulation of human antigen-presenting cells (APCs) including dendritic cells and macrophages with CpG-ODN or GpC-ODN or GpB-ODN at tolerted dose levels.
Original language | English |
---|---|
IPC | WO 2019/076478 |
Publication status | Published - 24 Apr 2019 |